Previous studies have shown that tumor-informed circulating tumor DNA (ctDNA) can improve clinical outcomes as an effective biomarker for treatment response monitoring (TRM) across various tumor types. A recent retrospective analysis has longitudinally examined ctDNA status and dynamics throughout surveillance and during TRM in patients with metastatic clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) treated with immunotherapy or targeted therapies. ...
nccRCC
Advertisement
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
The combination of ipilimumab/nivolumab may be a new standard in some subgroups of patients with metastatic nccRCC.
Drs. Barata and Tawagi provide updates in nccRCC, including SAMETA, PAPMET2, SUNNIFORECAST, and updated NCCN guidelines.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
Advertisement
Conference Coverage
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Advertisement
Advertisement
Latest News
Specificity findings varied, but some studies suggested similar or slightly higher rates in favor of MRI.
This new research shows no link between patient BMI and NMIBC recurrence, stage progression, or grade progression.
Patients with very high-risk disease saw greater benefit from long-term ADT use compared to those with high-risk disease.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.